PRQRProQR Therapeutics N.V.

PRQR Stock Price, Valuation & Chart | ProQR Therapeutics N.V.

Compare

$2.150+0.03 (+1.42%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology PRQR intrinsic value PRQR calculated fair value vs price

Overview Financials Dividends Ratios

PRQR Historical price chart

PRQR Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization226.41M

PE Ratio-4.67

EPS-0.46

Trading Volume388.55K

Today's High/Low2.21/2.12

Dividend Yield0.00

52 Week High/Low3.1/1.33

Shares Outstanding105.31M

PRQR Financial Statement

PRQR Analyst ratings

PRQR Analysis & performance metrics

PRQR Company profile

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily…

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated…

PRQR Management team

Name

Position

Sandra van der Kolk

Junior Financial Controller

Daniel Anton de BoerCEO

Founder, Chief Executive Officer & Member of Management Board

Cristina Lopez Lopez M.D., Ph.D.

Chief Medical Officer

Gerard Platenburg Ph.D.

Co-Founder, Chief Scientific Officer & Member of Management Board

Sheila Sponselee

Chief People & Operations Officer

Dennis HomCFO

Chief Financial Officer

Domenico Valerio Ph.D.

Founder & Independent Member of Supervisory Board

Sarah Cue Kiely

Vice President of Investor Relations & Corporate Communications

Name

Position

Sandra van der Kolk

Junior Financial Controller

Daniel Anton de BoerCEO

Founder, Chief Executive Officer & Member of Management Board

Cristina Lopez Lopez M.D., Ph.D.

Chief Medical Officer

Gerard Platenburg Ph.D.

Co-Founder, Chief Scientific Officer & Member of Management Board

Sheila Sponselee

Chief People & Operations Officer

Dennis HomCFO

Chief Financial Officer

Domenico Valerio Ph.D.

Founder & Independent Member of Supervisory Board

Sarah Cue Kiely

Vice President of Investor Relations & Corporate Communications

Management Team

Sandra van der Kolk

Junior Financial Controller

Daniel Anton de BoerCEO

Founder, Chief Executive Officer & Member of Management Board

Cristina Lopez Lopez M.D., Ph.D.

Chief Medical Officer

Gerard Platenburg Ph.D.

Co-Founder, Chief Scientific Officer & Member of Management Board

Sheila Sponselee

Chief People & Operations Officer

Dennis HomCFO

Chief Financial Officer

Domenico Valerio Ph.D.

Founder & Independent Member of Supervisory Board

Sarah Cue Kiely

Vice President of Investor Relations & Corporate Communications

Management

Sandra van der Kolk

Junior Financial Controller

Daniel Anton de BoerCEO

Founder, Chief Executive Officer & Member of Management Board

Cristina Lopez Lopez M.D., Ph.D.

Chief Medical Officer

Gerard Platenburg Ph.D.

Co-Founder, Chief Scientific Officer & Member of Management Board

Sheila Sponselee

Chief People & Operations Officer

Dennis HomCFO

Chief Financial Officer

Domenico Valerio Ph.D.

Founder & Independent Member of Supervisory Board

Sarah Cue Kiely

Vice President of Investor Relations & Corporate Communications

Total 8 executives

PRQR Frequently asked questions

What is ProQR Therapeutics N.V. (PRQR) Stock Price?

Current stock price of ProQR Therapeutics N.V. (PRQR) stock is $2.150. The stock price is +1.42% higher in the session. The intraday range can be seen from this page. Volume of ProQR Therapeutics N.V. (PRQR) stock is 388.55K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the ProQR Therapeutics N.V. (PRQR) stock price going up or down today?

The stock price of ProQR Therapeutics N.V. (PRQR) can change with earnings, company news, and overall market sentiment. ProQR Therapeutics N.V. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the ProQR Therapeutics N.V. stock expensive at its current price?

Whether ProQR Therapeutics N.V. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for PRQR on this page is -4.67. EPS on this page is -0.46. Compare those figures with peers and growth expectations before deciding if the current ProQR Therapeutics N.V. price is justified.

How has the stock price of ProQR Therapeutics N.V. (PRQR) performed historically?

Historical performance for ProQR Therapeutics N.V. (PRQR) is shown on the price chart on this page. Review multi-period moves alongside volume to see how PRQR reacted to past earnings and market events.

Should I buy ProQR Therapeutics N.V. (PRQR) stock, at this price?

Buying ProQR Therapeutics N.V. (PRQR) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.